A similar microbiologic profile in HIV-seropositive (HIV+) and seronegative (HIV-) women with pelvic inflammatory disease (PID). Multicenter HIV and PID Study Group.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

A similar microbiologic profile in HIV-seropositive (HIV+) and seronegative (HIV-) women with pelvic inflammatory disease (PID). Multicenter HIV and PID Study Group.

Abstr Gen Meet Am Soc Microbiol. 1994;94:553 (abstract no. C-356). Unique Identifier : AIDSLINE ASM94/94313102
Moorman A; Rice R; Irwin K; O'Sullivan M; Sperling R; Brodman M; Droese A; CDC, Atlanta, GA.

Abstract: To compare the microbiologic findings in HIV+ women with PID who may be immunosuppressed with those in HIV- women with PID, we started a prospective study in 1992 at two urban hospitals to evaluate women who have had PID diagnosed using standard criteria. Vaginal and endocervical secretions and endometrial biopsy tissue were tested for bacteria, viruses, and fungi, including common etiologic agents of PID. Preliminary data indicate that endometritis, based on standard histopathologic criteria, is significantly more common in HIV+ than HIV- women (HIV+ 7/10(70%), HIV- 17/55(31%), p < .05). HIV+ women tested to date were more likely than HIV- women to have endocervical human papilloma virus (HPV), including types associated with dysplasia (HIV+ 5/13(38%), HIV- 9/61(15%), p = .06). There were no significant differences between HIV+ and HIV- women in bacteria or fungi recovered from the vagina, cervix, or endometrium: endocervical gonorrhea, HIV+ 7/20(35%), HIV- 27/89(30%); endometrial gonorrhea, HIV+ 4/17(24%), HIV- 20/77(26%); endocervical chlamydia culture, HIV+ 2/11(18%), HIV- 11/67(16%); endocervical chlamydia DFA, HIV+ 5/17(29%), HIV- 18/81(22%); endometrial chlamydia, HIV+ 1/10(10%), HIV- 5/58(9%); endometrial facultative bacteria, HIV+ 9/16(56%), HIV- 54/74(72%); endometrial anaerobic bacteria, HIV+ 0/16, HIV- 10/76(13%). Preliminary data indicate that the microbiologic findings in HIV+ and HIV- women with PID appear similar. Our data do not suggest a need for changes in standard antibiotic treatment, but highlight the need for PAP smear screening for HPV cytologic changes.

Keywords: Adnexitis/EPIDEMIOLOGY/*MICROBIOLOGY Bacteria/ISOLATION & PURIF Cervix Uteri/MICROBIOLOGY Chlamydia Infections/EPIDEMIOLOGY Comparative Study Endometrium/MICROBIOLOGY Female Fungi/ISOLATION & PURIF Gonorrhea/EPIDEMIOLOGY Hospitals, Urban Human *HIV Seronegativity HIV Seropositivity/*MICROBIOLOGY Prospective Studies Vagina/MICROBIOLOGY ABSTRACT
941030
M94A0852

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .